NCT04146415

Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera

Status unknown NA Last updated 6 November 2019

What this trial tests

NA trial testing Spect scan with mTc99-PYP in Cardiac Amyloidosis in 30 participants. Status unknown.

Timeline

1 November 2019

Primary endpoint
30 November 2019

1 August 2020

Quick facts

Lead sponsor	Tel-Aviv Sourasky Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	1 November 2019
Primary completion	30 November 2019
Estimated completion	1 August 2020

Drugs / interventions tested

• Spect scan with mTc99-PYP

Conditions studied

• Cardiac Amyloidosis — all drugs for Cardiac Amyloidosis →

Sponsor

Tel-Aviv Sourasky Medical Center

Who can join

Adults 18 to 120, any sex, with Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Patients will undergo clinical and laboratory assessment, as well as imaging tests, at the discretion of the attending cardiologist and will be referred at their discretion to perform cardiac mapping using 99mTc-PYP.
2. On the day of the examination, the examiner will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Before conducting the test, the subject will undergo a brief interview by a physician, receive an explanation of the study and, if agreed, sign an agreement to perform a further examination on the CZT camera.
3. The patient will, as is customary, be installed on Vanflon 22 G periphery, through which a 15 millikiric (mCi) of

Publications & conference data

No peer-reviewed publications indexed yet for this trial.